Gong Yinhua, Shen Dan, Shi Jinfang, Jiang Ye, Gao Jie
Department of Pharmacy, the First Affiliated Hospital of Soochow University.
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University.
J Int Med Res. 2025 Jan;53(1):3000605241307845. doi: 10.1177/03000605241307845.
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19). This report describes the case of a patient with a prior history of kidney transplantation who received nirmatrelvir/ritonavir. In this case, sirolimus use was successfully stopped before nirmatrelvir/ritonavir treatment, and the nirmatrelvir/ritonavir trough concentration was determined. During nirmatrelvir/ritonavir treatment, the sirolimus trough concentration remained stable. This case highlights the risk associated with the concomitant administration of sirolimus and nirmatrelvir/ritonavir. Providers should therefore be cautious when prescribing nirmatrelvir/ritonavir to kidney transplant recipients currently receiving sirolimus, with caution exercised based on creatinine clearance.
奈玛特韦/利托那韦是一种经美国食品药品监督管理局批准用于治疗2019冠状病毒病（COVID-19）的新型药物组合。本报告描述了一名有肾移植病史的患者接受奈玛特韦/利托那韦治疗的病例。在此病例中，在奈玛特韦/利托那韦治疗前成功停用了西罗莫司，并测定了奈玛特韦/利托那韦的谷浓度。在奈玛特韦/利托那韦治疗期间，西罗莫司谷浓度保持稳定。该病例突出了西罗莫司与奈玛特韦/利托那韦联合使用的风险。因此，当为目前正在接受西罗莫司治疗的肾移植受者开具奈玛特韦/利托那韦处方时，医疗服务提供者应谨慎行事，并根据肌酐清除率谨慎用药。
